Newborn - Cell Therapies

Executive members

Translating Promise into Benefits

Monash Newborn is a world leader in the translation of stem cell therapies for newborn diseases from the bench to the bedside. Monash Newborn clinicians along with colleagues from The Ritchie Centre, Hudson Institute of Medical Research conducted the first-in-human trial of placental stem cells for preterm lung disease (bronchopulmonary dysplasia). They are currently involved in multicentre trials of a variety of stem cell therapies for newborn lung and brain conditions.


To facilitate translation of cell therapy solutions for neonatal conditions.

Mission statement

To improve and facilitate pre-clinical and clinical research translation of neonatal cell therapy possibilities by bringing together scientists, clinicians, commercial partners, trial coordinators, clinical and research staff interested in cell therapies.

Find out more about us from the sections below: